Sermorelin for Men: Studies and Label Warnings
Studies of Sermorelin that enrolled only men, what they measured, and what is still unproven.
- Strongest evidence
- Human RCT
- Studies enrolling only men
- 3
- in our evidence file (PubMed search, 11 Oct 2026)
- FDA status
- Not approved
Studies that enrolled only men
Each row is a study whose participants were described as men only. Results from one sex are not evidence for the other. Studies of animals and cells are not included.
| Study | Design | Population | Dose | First outcome |
|---|---|---|---|---|
| The Journal of clinical endocrinology and metabolism 1992, PMID 1379256 | Human RCT | Healthy old men (mean age 68.0 yr, nonobese); young men (n = 9) served as comparison. Peptide named GHRH-(1-29) in the abstract (the sermorelin sequence) | 0.5 mg (low) and 1 mg (high) GHRH-(1-29) | GH and IGF-I in old men: Two weeks of twice-daily GHRH injections reversed age-related decreases in GH and IGF-I in healthy old men; body composition was not measured. |
| American journal of men's health 2017, PMID 28830317 | Human observational | Men on testosterone therapy (retrospective chart review; 14 of 105 met compliance criteria), mean age 33.2 years. Received sermorelin together with GHRP-6 and GHRP-2, so the effect cannot be attributed to sermorelin alone | 100 mcg each of GHRP-6, GHRP-2 and sermorelin | Serum IGF-1: Mean IGF-1 rose from 159.5 ng/mL at baseline to 239.0 ng/mL after combined GHRP/sermorelin therapy (retrospective, multi-peptide combination, no control). |
| Metabolism: clinical and experimental 1997, PMID 9005976 | Human uncontrolled trial | Healthy, ambulatory, non-obese men aged 64 to 76 years with low baseline IGF-I levels. Peptide named GHRH (1-29) in the abstract (the sermorelin sequence) | 2 mg GHRH (1-29) | Body composition: Weight, BMI, waist-to-hip ratio, DEXA muscle and fat, muscle histology, glucose, insulin and lipids did not change. |
Peptides studied in men, compared
How strong is it?
A human randomized trial outweighs any number of animal studies. Animal and cell results show a mechanism worth testing, not that it works in people.
Men's health in plain terms
MedlinePlus notes that some conditions only affect men, such as prostate cancer and low testosterone.[8]
Studies that enrolled only men
In healthy old men, GHRH at 0.5 and 1 mg twice daily for 14 days raised GH and IGF-I; after the high dose they no longer differed from young men.[1]
In that study, baseline serum testosterone was lower in the older men than in the young men.[1]
In healthy men aged 64 to 76 given 2 mg nightly for 6 weeks, GHRH raised nocturnal GH release but did not change IGF-I levels, weight, or DEXA measures of muscle and fat.[3]
In a retrospective review of men on testosterone therapy, a three-times-daily combination of GHRP-6, GHRP-2 and sermorelin raised mean IGF-1 from 159.5 to 239.0 ng/mL; sermorelin was not given alone.[2]
Other peptides people research for men
All peptides for men, comparedCommon questions
Has Sermorelin been studied in men?
3 studies we summarise enrolled only men. Results from one sex are not evidence for the other.
Is Sermorelin approved for men?
No. Sermorelin is not FDA approved for any use in men or anyone else.
What does sermorelin do for men?
Older men given nightly injections showed no change in weight, body mass index or DEXA scans of muscle and fat.[3]
Does sermorelin cause side effects in men?
The cached men-only studies report no effect of treatment on fasting glucose or on blood chemistry and blood count profiles.[1]
More on Sermorelin
Sources
- 1Growth hormone (GH)-releasing hormone-(1-29) twice daily reverses the decreased GH and insulin-like growth factor-I levels in old men.The Journal of clinical endocrinology and metabolism · 1992PMID 1379256Accessed 2 Oct 2026
- 2Growth Hormone Secretagogue Treatment in Hypogonadal Men Raises Serum Insulin-Like Growth Factor-1 Levels.American journal of men's health · 2017PMID 28830317Accessed 2 Oct 2026
- 3Effects of single nightly injections of growth hormone-releasing hormone (GHRH 1-29) in healthy elderly men.Metabolism: clinical and experimental · 1997PMID 9005976Accessed 2 Oct 2026
- 4PubMed search: (sermorelin[tiab] OR Geref[tiab]) (34 results)PubMed · 2026pubmed.ncbi.nlm.nih.govAccessed 2 Oct 2026
- 5PubMed search: (sermorelin[tiab] OR "GHRH(1-29)"[tiab] OR "GRF(1-29)"[tiab] OR "GHRH 1-29"[tiab]) AND (elderly[tiab] OR aging[tiab] OR "older adults"[tiab] OR adults[tiab]) AND (treatment[tiab] OR therapy[tiab] OR administration[tiab]) (15 results)PubMed · 2026pubmed.ncbi.nlm.nih.govAccessed 2 Oct 2026
- 6PubMed search: (sermorelin[tiab] OR Geref[tiab]) AND (half-life[tiab] OR pharmacokinetic*[tiab]) (2 results)PubMed · 2026pubmed.ncbi.nlm.nih.govAccessed 2 Oct 2026
- 7PubMed search: (sermorelin[tiab] OR Geref[tiab] OR "GHRH(1-29)"[tiab] OR "GRF(1-29)"[tiab]) AND (adverse[tiab] OR "side effect*"[tiab] OR safety[tiab] OR tolerab*[tiab] OR toxicity[tiab] OR "case report"[pt]) (21 results)PubMed · 2026pubmed.ncbi.nlm.nih.govAccessed 11 Oct 2026
- 8Official web pageOfficial web page · web page
Found an error? Report a correction.